KAEL Gem-Vax posts promising NSCLC data; India expects vaccine market to soar;

> South Korea-based KAEL Gem-Vax, which we profiled in our report on promising pancreatic cancer drugs, has reported Phase II results of its GV1001 vaccine for Stage III non-small cell lung cancer. The company found GV1001 was well tolerated, immunizing the majority of NSCLC patients and establishing durable T-cell memory. A randomized trial is next. KAEL Gem-Vax release

> The Indian vaccine market is expected to grow 23% during 2011-2012, reaching $4.6 billion in revenue by 2017. Report

> Experts at the U.K.'s National Health Service are weighing whether they should recommend that all kids under 17 should get the flu shot. Report

> A vaccine injected directly into a pancreatic tumor could hold promise for patients whose cancer can't be surgically removed. The Phase I trial, which included just 6 patients, was conducted at the Cancer Institute of New Jersey. Article

And Finally... A new web-based reporting system could make vaccines more effective by speeding the data collection process following vaccination. Article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.